160 related articles for article (PubMed ID: 35192151)
1. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P
Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151
[TBL] [Abstract][Full Text] [Related]
2. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
4. Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.
Ervin C; Norcross L; Mallya UG; Fehnel S; Mittleman RS; Webster M; Haqq AM; Haws RM
Adv Ther; 2023 May; 40(5):2394-2411. PubMed ID: 36961653
[TBL] [Abstract][Full Text] [Related]
5. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM; Censani M
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
[TBL] [Abstract][Full Text] [Related]
6. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
Wabitsch M; Farooqi S; Flück CE; Bratina N; Mallya UG; Stewart M; Garrison J; van den Akker E; Kühnen P
J Endocr Soc; 2022 Jun; 6(6):bvac057. PubMed ID: 35528826
[TBL] [Abstract][Full Text] [Related]
7. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
Kühnen P; Clément K; Wiegand S; Blankenstein O; Gottesdiener K; Martini LL; Mai K; Blume-Peytavi U; Grüters A; Krude H
N Engl J Med; 2016 Jul; 375(3):240-6. PubMed ID: 27468060
[TBL] [Abstract][Full Text] [Related]
8. Setmelanotide: First Approval.
Markham A
Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
Lazareva J; Brady SM; Yanovski JA
Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
[TBL] [Abstract][Full Text] [Related]
11. Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers.
Dubern B; Lourdelle A; Clément K
JCEM Case Rep; 2023 May; 1(3):luad041. PubMed ID: 37908575
[TBL] [Abstract][Full Text] [Related]
12. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
13. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.
Forsythe E; Haws RM; Argente J; Beales P; Martos-Moreno GÁ; Dollfus H; Chirila C; Gnanasakthy A; Buckley BC; Mallya UG; Clément K; Haqq AM
Orphanet J Rare Dis; 2023 Jan; 18(1):12. PubMed ID: 36647077
[TBL] [Abstract][Full Text] [Related]
14. A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway.
Kanti V; Puder L; Jahnke I; Krabusch PM; Kottner J; Vogt A; Richter C; Andruck A; Lechner L; Poitou C; Krude H; Gottesdiener K; Clément K; Farooqi IS; Wiegand S; Kühnen P; Blume-Peytavi U
Skin Pharmacol Physiol; 2021; 34(6):307-316. PubMed ID: 34058738
[TBL] [Abstract][Full Text] [Related]
15. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
[TBL] [Abstract][Full Text] [Related]
16. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
[TBL] [Abstract][Full Text] [Related]
17. Could setmelanotide be the game-changer for acquired hypothalamic obesity?
van Santen HM; Denzer C; Müller HL
Front Endocrinol (Lausanne); 2023; 14():1307889. PubMed ID: 38239988
[TBL] [Abstract][Full Text] [Related]
18. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
[TBL] [Abstract][Full Text] [Related]
19. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
Roth CL; Scimia C; Shoemaker AH; Gottschalk M; Miller J; Yuan G; Malhotra S; Abuzzahab MJ
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):380-389. PubMed ID: 38697184
[TBL] [Abstract][Full Text] [Related]
20. Melanocortin signaling is decreased during neurotoxin-induced transient hyperphagia and increased body-weight gain.
Dube MG; Pu S; Kalra SP; Kalra PS
Peptides; 2000 Jun; 21(6):793-801. PubMed ID: 10958999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
